Atezolizumab in combination with carboplatin and etoposide has been approved in the UK for the frontline treatment of patients with extensive-stage small cell lung cancer.
The rate of global molecular testing is low and is limited by a number of factors, including cost, quality, turn-around time, access, and lack of awareness of testing.
The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).
The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.
Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.
Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.
The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.
R. Lor Randall, MD, FACS, discusses the cautions medical oncologists should take for their patients with bone sarcomas who undergo limb preservation with osteointegration, and the importance of keeping orthopedic oncologists in the loop.
Raymond Liu, MD, shed light on the benefits and challenges of utilizing telehealth in oncology and shared advice on how to implement this approach in practice.
LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.